2,618 results on '"Morrow, Monica"'
Search Results
202. Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
203. Response to: “Letter to the Editor: Is Low-Volume Disease in the Sentinel Node After Neoadjuvant Chemotherapy an Indication for Axillary Dissection? Miscalculation of Sensitivity and False Negative Rate”
204. Correction to: Is Low-Volume Disease in the Sentinel Node After Neoadjuvant Chemotherapy an Indication for Axillary Dissection?
205. Contralateral Breast Cancer Risk in Women with Ductal Carcinoma In Situ: Is it High Enough to Justify Bilateral Mastectomy?
206. Tumor Biology Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Patients Presenting with Locally Advanced Breast Cancer
207. Standard Pathologic Features Can Be Used to Identify a Subset of Estrogen Receptor-Positive, HER2 Negative Patients Likely to Benefit from Neoadjuvant Chemotherapy
208. Meta-analysis of pre-operative magnetic resonance imaging (MRI) and surgical treatment for breast cancer
209. Outcomes for Women with Minimal-Volume Ductal Carcinoma In Situ Completely Excised at Core Biopsy
210. The 21-gene recurrence score in special histologic subtypes of breast cancer with favorable prognosis
211. The Optimal Treatment Plan to Avoid Axillary Lymph Node Dissection in Early-Stage Breast Cancer Patients Differs by Surgical Strategy and Tumor Subtype
212. 21-Gene recurrence score and locoregional recurrence in lymph node-negative, estrogen receptor-positive breast cancer
213. Surgeon Attitudes and Use of MRI in Patients Newly Diagnosed with Breast Cancer
214. Do Calcifications Seen on Mammography After Neoadjuvant Chemotherapy for Breast Cancer Always Need to Be Excised?
215. New Guidelines on the Adequacy of Lumpectomy Margin Width in Patients with Ductal Carcinoma In Situ
216. Impact of self-reported data on the acquisition of multi-generational family history and lifestyle factors among women seen in a high-risk breast screening program: a focus on modifiable risk factors and genetic referral
217. Evaluation of Local and Distant Recurrence Patterns in Patients with Triple-Negative Breast Cancer According to Age
218. Is Routine Axillary Imaging Necessary in Clinically Node-Negative Patients Undergoing Neoadjuvant Chemotherapy?
219. Recurrence risk perception and quality of life following treatment of breast cancer
220. Society of Surgical Oncology Breast Disease Working Group Statement on Prophylactic (Risk-Reducing) Mastectomy
221. Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update
222. Social Work's Role in Bridging Breast Cancer Care Gaps—Reply.
223. Breast Cancer in Elderly Women
224. Professionalism in the Approach to the Patient
225. Changes in the Diagnoses of Breast Core Needle Biopsies on Second Review at a Tertiary Care Center
226. ASO Visual Abstract: Can We Forego Sentinel Lymph Node Biopsy in Women ≥50 Years of Age with Early-Stage Hormone Receptor-Positive HER2-Negative Special Histologic Subtype Breast Cancer?
227. Can We Forgo Sentinel Lymph Node Biopsy in Women Aged ≥ 50 Years with Early-Stage Hormone-Receptor-Positive HER2-Negative Special Histologic Subtype Breast Cancer?
228. ASO Visual Abstract: Patient-Reported Outcome Measures in Patients with Clinical T4 Breast Cancer Treated with Mastectomy With and Without Reconstruction
229. ASO Visual Abstract: Axillary Staging Is Not Justified in Postmenopausal Clinically Node-Negative Women Based on Nodal Disease Burden
230. Patient-Reported Outcome Measures for Patients Who Have Clinical T4 Breast Cancer Treated via Mastectomy with and Without Reconstruction
231. Nipple-Sparing Mastectomy and Immediate Reconstruction: A Propensity Score–Matched Analysis of Satisfaction and Quality of Life
232. Ductal Carcinoma in Situ
233. Applications for Breast Magnetic Resonance Imaging
234. Society of Surgical Oncology–American Society for Radiation Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Stages I and II Invasive Breast Cancer
235. Bilateral implant reconstruction does not affect the quality of postmastectomy radiation therapy
236. Refining Risk Assessment in Women With Benign Breast Disease: An Ongoing Dilemma
237. Reducing Overtreatment of Cancer With Precision Medicine: Just What the Doctor Ordered
238. Management of the Node-Positive Axilla in Breast Cancer in 2017: Selecting the Right Option
239. Contralateral breast cancers: Independent cancers or metastases?
240. Surgeon Influence on Variation in Receipt of Contralateral Prophylactic Mastectomy for Women With Breast Cancer
241. Reply to “Multicentric Ipsilateral Invasive Breast Carcinomas Might Have Higher 21-Gene Recurrence Score Compared with Multifocal Ipsilateral Invasive Breast Carcinomas”
242. Breast Cancer in Elderly Women
243. Treatment decisions and employment of breast cancer patients: Results of a population‐based survey
244. The association between patient attitudes and values and the strength of consideration for contralateral prophylactic mastectomy in a population‐based sample of breast cancer patients
245. ASO Author Reflections: Biological Diversity of Histologic Subtypes
246. ASO Author Reflections: Low-Volume Sentinel Node Disease After Neoadjuvant Chemotherapy is Still an Indication for Axillary Dissection
247. Axillary lymph node dissection: Dead or still alive?
248. Prevention of Breast Cancer
249. The Association of Surgical Margins and Local Recurrence in Women with Ductal Carcinoma In Situ Treated with Breast-Conserving Therapy: A Meta-Analysis
250. How Often Does Neoadjuvant Chemotherapy Avoid Axillary Dissection in Patients With Histologically Confirmed Nodal Metastases? Results of a Prospective Study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.